Ovarian / Tubal / Peritoneal Cancer FIGO 2014 Stage — free guideline decision tool

Assign the FIGO 2014 stage for ovarian, fallopian-tube and primary peritoneal cancer from confinement, pelvic spread, retroperitoneal nodes and distant disease. Instant, browser-side.

I confined to gonads (IA/IB/IC1 intraoperative rupture/IC2 pre-op rupture or surface/IC3 washings positive); II pelvic extension (IIA/IIB); III nodes or extrapelvic peritoneum (IIIA1 i ≤ 10 / ii > 10 mm, IIIA2 micro, IIIB ≤ 2 cm, IIIC > 2 cm); IVA pleural cytology, IVB parenchymal/extra-abdominal.

Staging and management direction for ovarian/tubal/peritoneal cancer, which share a single FIGO system.

Splenic/hepatic capsule (surface) disease is IIIC, but hepatic/splenic parenchymal metastasis is IVB — a common staging pitfall. Stage IC is split by mechanism: IC1 surgical spill, IC2 pre-operative rupture or surface tumour, IC3 positive ascites/washings. Early disease has comprehensive staging surgery ± platinum/taxane chemotherapy; advanced disease has cytoreduction aiming for no gross residual. BRCA-mutant / HRD-positive advanced disease is offered PARP-inhibitor maintenance.

For licensed clinicians and clinical researchers. Interpret results with history, investigations and local protocols; not a diagnosis or prescription, and not a substitute for multidisciplinary decision-making or local guidelines.

Calculation runs locally in the browser; inputs and results are not uploaded. For licensed clinicians only; interpret with history, investigations and local protocols — not a diagnosis or prescription.

Inputs: When confined to ovary/tube IC1 — intraoperative rupture (surgical spill), Pelvic extension (below pelvic brim) IIA — uterus/tube/ovary, Retroperitoneal nodes (nodes only, no peritoneal spread) IIIA1(i) — ≤ 10 mm, Extrapelvic peritoneal spread IIIA2 — microscopic extrapelvic peritoneum, Distant metastasis IVA — pleural effusion, cytology positive → Result: FIGO stage Stage IVA（FIGO 2014 stage: Stage IVA (pleural effusion, cytology positive), Management direction: Cytoreductive surgery (aim for optimal / no gross residual) + platinum/paclitaxel chemotherapy ± bevacizumab; BRCA-mutant / HRD-positive → PARP inhibitor maintenance; bulky or unresectable advanced disease may have neoadjuvant chemotherapy then interval cytoreduction, Notes: Ovarian/tubal/peritoneal cancers share one staging system; stage by the highest level of involvement; retroperitoneal nodes need cytologic or histologic confirmation; splenic/hepatic capsule involvement is IIIC, whereas hepatic/splenic parenchymal metastasis is IVB） Inputs: When confined to ovary/tube IA — unilateral, capsule intact, no surface tumour, washings negative, Pelvic extension (below pelvic brim) None, Retroperitoneal nodes (nodes only, no peritoneal spread) None, Extrapelvic peritoneal spread None, Distant metastasis None → Result: FIGO stage Stage IA（FIGO 2014 stage: Stage IA (unilateral, capsule intact, washings negative), Management direction: Comprehensive staging surgery (total hysterectomy + BSO + omentectomy + peritoneal biopsies + pelvic/para-aortic node assessment ± washings); IA/IB low-grade may be observed, IC or high-grade → platinum + paclitaxel adjuvant chemotherapy; fertility-sparing may be considered in selected early disease, Notes: Ovarian/tubal/peritoneal cancers share one staging system; stage by the highest level of involvement; retroperitoneal nodes need cytologic or histologic confirmation; splenic/hepatic capsule involvement is IIIC, whereas hepatic/splenic parenchymal metastasis is IVB）